Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q30694702)
Watch
English
Efficacy and safety of laquinimod in multiple sclerosis: current status
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
title
Efficacy and safety of laquinimod in multiple sclerosis: current status
(English)
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
main subject
multiple sclerosis
0 references
author
Serena Ruggieri
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
Claudio Gasperini
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
author name string
Shalom Haggiag
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
publication date
1 November 2013
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
published in
Therapeutic advances in neurological disorders
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
volume
6
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
issue
6
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
page(s)
343-352
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
cites work
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
20 June 2018
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
20 June 2018
Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
20 June 2018
Placebo-controlled trial of oral laquinimod for multiple sclerosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
20 June 2018
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
20 June 2018
Cost of multiple sclerosis by level of disability: a review of literature.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
20 June 2018
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
20 June 2018
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825117
retrieved
11 August 2018
Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24228070
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24228070
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24228070
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24228070
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1177/1756285613499424
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
PMCID
3825117
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
PubMed ID
24228070
1 reference
stated in
Europe PubMed Central
PMCID
3825117
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24228070%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 February 2020
ResearchGate publication ID
258524008
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit